Ven Bio Partners LLC Akero Therapeutics, Inc. Transaction History

Ven Bio Partners LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$10.15 - $34.05 $16 Million - $53.6 Million	-1,575,181 Reduced 72.53%	596,483 $20.3 Million
Q4 2021 Feb 14, 2022	SELL	$19.87 - $26.24 $578,495 - $763,951	-29,114 Reduced 1.32%	2,171,664 $45.9 Million
Q2 2021 Aug 16, 2021	SELL	$24.81 - $32.35 $6.04 Million - $7.88 Million	-243,533 Reduced 9.96%	2,200,778 $54.6 Million
Q3 2020 Nov 16, 2020	SELL	$30.79 - $39.92 $21.7 Million - $28.2 Million	-705,708 Reduced 22.4%	2,444,311 $75.3 Million
Q1 2020 May 15, 2020	SELL	$12.8 - $27.05 $10.1 Million - $21.4 Million	-790,524 Reduced 20.06%	3,150,019 $66.8 Million
Q4 2019 Feb 13, 2020	SELL	$17.37 - $27.27 $248,651 - $390,370	-14,315 Reduced 0.36%	3,940,543 $87.5 Million
Q2 2019 Aug 14, 2019	BUY	$18.08 - $19.83 $71.5 Million - $78.4 Million	3,954,858 New	3,954,858 $68.2 Million

194

74.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.37B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Ven Bio Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Ven Bio Partners LLC with notifications on news.